MIM
RXDX

MetLife Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

MetLife Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Upgrade to unlock
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
2023
Q1 		$1.97M Hold
2022
Q4 		$2.01M Buy
2022
Q3 		$1.03M Hold
2022
Q2 		$493K Hold
2022
Q1 		$659K Buy
2021
Q4 		$444K Buy
2021
Q3 		$116K Buy